Schrodinger Inc

Schrodinger Inc(SDGR)股票分析

$24.500

+0.720 (+2.94%)收盤時

Loading chart…
最高
24.890
開盤
23.890
成交量加權均價
24.22
成交量
1.26M
市值
1.41B
最低
23.260
成交金額
30.62M
企業價值/稅息折舊攤銷前利潤(TTM)
-9.43

Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.

AI 分析 of Schrodinger Inc (SDGR)

持有

Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.

估值指標

Schrodinger Inc(SDGR)目前預期本益比為 0.00,5 年平均預期本益比為 -8.74。

預期本益比

合理
5 年均值 P/E
-8.74
目前P/E
0.00
高估
4.11
低估
-21.60

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-8.32
目前EV/EBITDA
-9.43
高估
-4.93
低估
-11.71

預期股價營收比

合理
5 年均值 P/S
8.19
目前P/S
7.15
高估
11.85
低估
4.54

Alphio AI 對 SDGR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SDGR

$27.96

情境價格

基

基準

基準 · 50%SDGR

$23.51

情境價格

悲

悲觀

悲觀 · 25%SDGR

$23.10

情境價格

持有 SDGR 的大戶

R

Rubric Capital Management LP

+ 持有SDGR

+0.39%

3個月報酬率

事件時間軸

2026-10-26 (ET)

09:00:00

Schrodinger Grants 5,716 Restricted Stock Units to Five New Employees

2026-09-17 (ET)

12:00:00

Stocks Surge as Oil Prices Retreat

09:00:00

Schrodinger Grants 2,243 Restricted Stock Units to Three New Employees

2026-09-09 (ET)

07:30:00

Schrodinger Forms Tectora and Secures $55M Investment

2026-08-05 (ET)

17:00:00

Schrodinger Provides Financial Guidance for FY 2026

資訊

SDGR 常見問題 —— 由 Alphio AI 解答

Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).

Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易